NIH-led research on structural racism was published Friday, even as the Trump administration has cancelled and discredited ...
A feud between the FDA's Vinay Prasad and his staff is threatening the future of the center that regulates vaccines, ...
Vinay Prasad’s tumultuous tenure at the Food and Drug Administration has entered a new, even rockier era: a slow-boiling feud ...
Dozens of scientists are considering leaving the Center for Biologics Evaluation and Research, where Prasad serves as ...
A month’s supply of Miebo requires $800 and a prescription in the U.S. In Europe, it’s over-the-counter and $20.
Large private insurers have continued to call out purportedly overzealous coding and billing as a source of ballooning health ...
Medicare administrative contracts have proposed eliminating coverage for peripheral nerve block procedures for chronic pain ...
Health care has become a central issue in this year’s elections, a sign of parties' midterm strategies to come.
A new drug-sales king has been crowned. Eli Lilly’s diabetes and weight-loss drug tirzepatide, marketed under the Mounjaro ...
Has BridgeBio's business model worked? How are executives at Moderna dealing with the company's slump? Find out on the new episode of "The Readout LOUD." ...
The stock market pummeled Cigna after the company revealed its new plan to ditch pharmacy benefit rebates will lower that segment’s profit ...
Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback